James W Jakub
Overview
Explore the profile of James W Jakub including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
1518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar A, Jakub J, Lester S, Markovic S, Baum C
J Am Acad Dermatol
. 2025 Mar;
PMID: 40074149
In-transit metastases (ITM) are estimated to occur in 5-10% of primary cutaneous melanomas. They are classified as stage III disease in the American Joint Committee on Cancer classification system and...
2.
Suman S, Nevala W, Leontovich A, Jakub J, Geng L, McLaughlin S, et al.
Front Mol Biosci
. 2025 Feb;
11:1522717.
PMID: 39911494
Cytokines play a crucial role in mediating cell communication within the tumor microenvironment (TME). Tumor-associated macrophages are particularly influential in the regulation of immunosuppressive cytokines, thereby supporting tumor metastasis. The...
3.
Szabo Yamashita T, Yeh V, Lund S, Rivera M, McKenzie T, Stulak J, et al.
Surg Pract Sci
. 2025 Jan;
11():100134.
PMID: 39845154
Design: Retrospective single-institution review of general surgery resident evaluations (2008-2020). Demographic characteristics, level of training and internal evaluation variables were collected. Percentile distribution and association between subjective and objective measures...
4.
Van Decar S, Carpenter E, Adams A, Chick R, Clifton G, Stojadinovic A, et al.
Cancer Treat Res Commun
. 2024 Sep;
41:100843.
PMID: 39305541
Background: The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is produced from dendritic cells (DC) loaded ex vivo with autologous tumor lysate (TL). TLPLDC has been shown to decrease...
5.
Mutter R, Golafshar M, Buras M, Comstock B, Jacobson M, DeWees T, et al.
Int J Radiat Oncol Biol Phys
. 2024 Sep;
121(2):352-364.
PMID: 39299551
Purpose: The optimal approach for partial breast irradiation (PBI) is unknown. We investigated a novel de-intensified 3-fraction PBI regimen for photons, protons, and brachytherapy. Methods And Materials: A multicenter nonrandomized...
6.
Rosenberger L, Thomas S, Hieken T, Gallagher K, Spanheimer P, Neuman H, et al.
Breast Cancer Res Treat
. 2024 Sep;
209(2):275-282.
PMID: 39269552
Purpose: Germline genetic mutations in women with phyllodes tumors (PT) are understudied, although some describe associations of PT with various mutations. We sought to determine the prevalence of pathogenic/likely pathogenic...
7.
Hatcher K, Leon A, Cornell L, Jakub J, McLaughlin S, Maimone S
Clin Imaging
. 2024 Aug;
113():110242.
PMID: 39088932
Purpose: Acute nipple inversion can be unsettling for patients and is sometimes associated with an underlying breast malignancy. It also poses a diagnostic challenge with lack of consensus management guidelines....
8.
Suman S, Nevala W, Leontovich A, Ward C, Jakub J, Kim Y, et al.
Biomolecules
. 2024 Jul;
14(7).
PMID: 39062552
CD36 expression in both immune and non-immune cells is known to be directly involved in cancer metastasis. Extracellular vesicles (EVs) secreted by malignant melanocytes play a vital role in developing...
9.
Jakub J, Boughey J, Hieken T, Piltin M, Forte A, Vijayasekaran A, et al.
Ann Surg Oncol
. 2024 Jul;
31(11):7349-7359.
PMID: 38955992
Background: Immediate lymphatic reconstruction (ILR) has been proposed to decrease lymphedema rates. The primary aim of our study was to determine whether ILR decreased the incidence of lymphedema in patients...
10.